Pharmacyte Biotech, INC 8-K filings

PharmaCyte Biotech stockholders approved an increase in equity incentive shares and authorized a potential reverse stock split at the 2026 annual meeting.

PharmaCyte Biotech, Inc. received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, initiating a 180-day compliance period.

Q/C Technologies, formerly TNF Pharmaceuticals, reported significant net losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern and facing a Nasdaq minimum bid price deficiency.

PharmaCyte Biotech, Inc. stockholders approved key proposals, including an increase of 2.25 million shares for its 2022 Equity Incentive Plan and authorization for common stock issuance to comply with Nasdaq rules.

PharmaCyte Biotech invests an additional $3 million in TNF Pharmaceuticals to support its new license for a breakthrough light-speed computing platform aimed at cryptocurrency and blockchain applications.

PharmaCyte Biotech, Inc. announced a $7 million private placement of Series C convertible preferred stock and warrants, primarily from existing investors, to strengthen its balance sheet and pursue strategic alternatives.

PharmaCyte Biotech held its annual meeting on April 24, 2025, electing five directors, ratifying its accounting firm, and approving executive compensation in a non-binding advisory vote.

PharmaCyte Biotech announces the resignation of Marcum LLP as its independent registered accounting firm and the appointment of CBIZ CPAs P.C., effective February 21, 2025, following Marcum's acquisition of CBIZ's attest business.

PharmaCyte Biotech has made a $7 million strategic investment in MyMD Pharmaceuticals, a biopharmaceutical company focused on inflammatory diseases.

PharmaCyte Biotech held its annual meeting on April 29, 2024, where shareholders elected five directors, ratified the selection of Marcum LLP as the independent auditor, and approved executive compensation on a non-binding advisory basis.